Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Pamela Munster

Description

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Official Title

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Keywords

Solid Tumor TGF Beta Paclitaxel Gemcitabine Albumin-Bound Paclitaxel Cisplatin LY3200882 LY3300054 nab-Paclitaxel Intensity Modulated Radiotherapy LY3200882 Schedule 1 Escalation LY3200882 Schedule 2 Escalation LY3200882 Schedule 1 Expansion LY3200882 Schedule 2 Expansion LY3200882 + Gemcitabine + nab-Paclitaxel LY3200882 + Cisplatin + Radiation

Eligibility

You can join if…

Open to people ages 18 years and up

  • The participant must have histological or cytological evidence of cancer.
  • Have adequate organ function.
  • Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
  • Are able to swallow capsules and tablets.

You CAN'T join if...

  • Have moderate or severe cardiovascular disease.
  • Have a serious concomitant systemic disorder.
  • Have acute leukemia.

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94115 United States
  • University of Texas MD Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States

Lead Scientist

  • Pamela Munster
    Professor, Medicine. Authored (or co-authored) 92 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
more information about this study: A Study of LY3200882 in Participants With Solid Tumors
ID
NCT02937272
Phase
Phase 1
Study Type
Interventional
Last Updated